LISATA THERAP.INC.DL-001 (F:8NE) — Market Cap & Net Worth
Market Cap & Net Worth: LISATA THERAP.INC.DL-001 (8NE)
LISATA THERAP.INC.DL-001 (F:8NE) has a market capitalization of $7.83 Million (€6.69 Million) as of August 5, 2026. Listed on the F stock exchange, this Germany-based company holds position #27630 globally and #2381 in its home market, demonstrating a -57.51% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying LISATA THERAP.INC.DL-001's stock price €0.74 by its total outstanding shares 9106391 (9.11 Million). Review LISATA THERAP.INC.DL-001 debt and liabilities to assess the company's total debt and financial obligations.
LISATA THERAP.INC.DL-001 Market Cap History: 2015 to 2026
LISATA THERAP.INC.DL-001's market capitalization history from 2015 to 2026. Data shows change from $1.58 Billion to $7.83 Million (-39.86% CAGR).
LISATA THERAP.INC.DL-001 Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how LISATA THERAP.INC.DL-001's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
98.32x
LISATA THERAP.INC.DL-001's market cap is 98.32 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2024 | $29.81 Million | $1.00 Million | -$19.98 Million | 29.81x | N/A |
| 2025 | $16.71 Million | $170.00K | -$16.59 Million | 98.32x | N/A |
Competitor Companies of 8NE by Market Capitalization
Companies near LISATA THERAP.INC.DL-001 in the global market cap rankings as of August 5, 2026.
Key companies related to LISATA THERAP.INC.DL-001 by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #222 globally with a market cap of $110.45 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #423 globally with a market cap of $64.60 Billion USD.
- Argen-X (BR:ARGX): Ranked #541 globally with a market cap of $49.55 Billion USD ( €42.38 Billion EUR).
- UCB SA (BR:UCB): Ranked #564 globally with a market cap of $47.34 Billion USD ( €40.49 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #222 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $110.45 Billion | $470.72 |
| #423 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $64.60 Billion | $759.24 |
| #541 | Argen-X | BR:ARGX | $49.55 Billion | €722.20 |
| #564 | UCB SA | BR:UCB | $47.34 Billion | €221.40 |
LISATA THERAP.INC.DL-001 Historical Marketcap From 2015 to 2026
Between 2015 and today, LISATA THERAP.INC.DL-001's market cap moved from $1.58 Billion to $ 7.83 Million, with a yearly change of -39.86%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €7.83 Million | -53.18% |
| 2025 | €16.71 Million | -43.93% |
| 2024 | €29.81 Million | +12.90% |
| 2023 | €26.40 Million | +14.81% |
| 2022 | €23.00 Million | -80.00% |
| 2021 | €114.98 Million | -38.46% |
| 2020 | €186.84 Million | -40.61% |
| 2019 | €314.60 Million | -34.11% |
| 2018 | €477.49 Million | +4.36% |
| 2017 | €457.53 Million | +11.00% |
| 2016 | €412.17 Million | -73.85% |
| 2015 | €1.58 Billion | -- |
End of Day Market Cap According to Different Sources
On Aug 4th, 2026 the market cap of LISATA THERAP.INC.DL-001 was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $7.83 Million USD |
| MoneyControl | $7.83 Million USD |
| MarketWatch | $7.83 Million USD |
| marketcap.company | $7.83 Million USD |
| Reuters | $7.83 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About LISATA THERAP.INC.DL-001
Lisata Therapeutics, Inc., a clinical-stage pharmaceutical company, engages in the discovery, development, and commercialization of therapies for the treatment of solid tumors and other diseases. Its investigational product is certepetide, which is in Phase 2 clinical studies for the treatment of solid tumors, such as metastatic pancreatic ductal adenocarcinoma, cholangiocarcinoma, appendiceal ca… Read more